RRD With Bruton Tyrosine Kinase Inhibitor Therapy
This case report describes a woman in her 70s with a history of breast cancer and chronic lymphocytic leukemia who presented with a painful rash of the bilateral chest extending onto the flanks. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 27, 2024 Category: Dermatology Source Type: research
Hyperhidrosis and Hypermobility Spectrum Disorders Among Adolescents
This cross-sectional study assesses the prevalence and risk of excessive sweating and joint hypermobility in Israeli adolescents aged 16 to 19 years. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 27, 2024 Category: Dermatology Source Type: research
Quest for a More Accurate Diagnosis of Cellulitis
For most physicians, cellulitis is one of the classic “I know it when I see it” diseases, in which a diagnosis is rendered, antibiotics initiated, and the patient is quickly out of sight and out of mind. Unfortunately, being common and being simple are not the same, and more than one-third of patients suspected to have cellulitis are incorrectly di agnosed. The cumulative burden of misdiagnosis results in unnecessary antibiotic use, hospitalizations, and tremendous health care expenditures. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 27, 2024 Category: Dermatology Source Type: research
Outcome Measurement Instruments for Dermatologic Adverse Events in Cancer Trials
This systematic review evaluates heterogeneity and quality of clinician-reported and patient-reported outcome measures for assessing dermatologic adverse events related to systemic cancer treatment. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 20, 2024 Category: Dermatology Source Type: research
JAMA Dermatology Peer Reviewers in 2023
We sincerely thank the 657 peer reviewers who completed manuscript reviews for JAMA Dermatology in 2023. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 20, 2024 Category: Dermatology Source Type: research
Considerations Regarding Mohs Surgery for Early-Stage Merkel Cell Carcinoma —Reply
In Reply We appreciate the interest in our article by Faries and Venna et al as well as their comments on the analysis. While we agree that there are inherent limitations to retrospective studies of survival outcomes using registry data, we believe that it is prudent to glean what insights we can from these datasets given the lack of large-scale studies of rare cancers, such as Merkel cell carcinoma (MCC), in the existing literature. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 20, 2024 Category: Dermatology Source Type: research
Reanalysis of Study After Removal of Participants in 1 Trial of Upadacitinib for Atopic Dermatitis
To the Editor On behalf of my coauthors, I write regarding a previously published article, “Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials,” which was published online first on April 12, 2023, and in the May 2023 issue of JAMA Dermatology. In this a rticle, we reported an analysis of 552 adolescents enrolled in 3 multicenter randomized clinical trials in more than 20 countries to assess the efficacy and safety of upadacitinib to treat moderate-to-severe atopic dermatitis in adolescen...
Source: JAMA Dermatology - March 20, 2024 Category: Dermatology Source Type: research
Considerations Regarding Mohs Surgery for Early-Stage Merkel Cell Carcinoma
To the Editor We read with interest the analysis comparing unadjusted overall survival (OS) of Mohs micrographic surgery (MMS) vs excision using the National Cancer Database (NCDB) for stage 1 and 2 Merkel cell carcinoma (MCC). MMS was associated with improved OS vs wide local excision (WLE) with an approximately 40% reduction in deaths. However, we cannot endorse the authors ’ conclusion that MMS “may provide a more effective treatment for MCC” as it is inconsistent with what is known about MCC. A systematic review of 31 studies (retrospective and case series) comparing WLE and MMS for MCC did not show a difference ...
Source: JAMA Dermatology - March 20, 2024 Category: Dermatology Source Type: research
Considerations Regarding Mohs Surgery for Early-Stage Merkel Cell Carcinoma
To the Editor I read with interest the recent article by Cheraghlou and colleagues regarding primary tumor excision techniques in Merkel cell carcinoma (MCC). The article ’s central observation, an association between the use of Mohs surgery and improved overall survival (OS) compared with wide excision, appears to be accurate. However, the assertion that Mohs surgery provides a “more effective treatment for MCC primary tumors than conventional” wide local exci sion does not appear to be supported by the presented data. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 20, 2024 Category: Dermatology Source Type: research
JAMA Dermatology —The Year in Review, 2023
2023 Was another exceptional year for JAMA Dermatology. The editorial team evaluated a steady number of article submissions (Table). A total of 956 of 2756 submissions were research articles. Acceptance rates remained stable, with 10% of submissions overall and 11% of research articles accepted for publication. The journal continued to maintain its goal of reducing the time to publication, keeping the median days of acceptance to publication to 63 days while offering timely editorial decisions, including maintaining the median time to first decision without peer review to 4 days. The median time of receipt to first decisio...
Source: JAMA Dermatology - March 20, 2024 Category: Dermatology Source Type: research
Improved Dermatologist, Patient, and Oncologist Collaboration Needed During Cancer Drug Development
Cancer is a leading cause of death internationally, with 19 million new cases diagnosed worldwide in 2020, and approximately 25% of adult patients with cancer participate in at least 1 cancer clinical research study. The development of newer systemic cancer therapies through oncology clinical trials has been accompanied by an increasing number of patients with cancer surviving more than 5 years as well as a rising prevalence of cancer treatment-related dermatologic adverse events (DAEs). Precise diagnosis and grading and reporting of cutaneous toxicities due to systemic chemotherapies including traditional chemotherapies, ...
Source: JAMA Dermatology - March 20, 2024 Category: Dermatology Source Type: research
Errors in Abstract, Results, Tables, and Figures
This article has been corrected online. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 20, 2024 Category: Dermatology Source Type: research
Pigmentary Changes in a Woman With Oral Lichen Planus
A woman in her 60s presented with oral lichen planus on hands and cheeks since childhood and also present in her parent and sibling. What is your diagnosis? (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 20, 2024 Category: Dermatology Source Type: research
Orofacial Anomalies in Kindler Epidermolysis Bullosa
This cohort study examines whether hypoplastic pitted amelogenesis imperfecta is a feature of Kindler epidermolysis bullosa, a genetic skin-blistering disease associated with recessive inherited pathogenic variants in FERMT1, which encodes kindlin-1. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 20, 2024 Category: Dermatology Source Type: research
Adjuvant Immunotherapy in Stage II Melanoma
This Viewpoint reviews the evidence for immune checkpoint inhibitor use in the adjuvant setting, discusses the individual and societal risks, benefits, and costs associated with immune checkpoint inhibitors, and highlights the need for more targeted patient selection approaches. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 13, 2024 Category: Dermatology Source Type: research
